Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

+0.59%

-1.61%

Adaptive Biotechnologies

ADPT

13.58

+0.59%

Pfizer Inc.

PFE

26.97

-1.61%

Dec 15 (Reuters) - Adaptive Biotechnologies ADPT.O said on Monday it has signed two non-exclusive deals with Pfizer PFE.N to support research in rheumatoid arthritis and other immune-related diseases.

Adaptive said it will earn up to $890 million, including upfront fees and milestone payments tied to research progress, product development and sales.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Krishna Chandra Eluri)

((Padmanabhan.Ananthan@thomsonreuters.com;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.